Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIO Survey Seeks To Uncover Inconsistencies In Review Divisions

This article was originally published in The Pink Sheet Daily

Executive Summary

The trade group will ask members to characterize their pre-clinical and clinical stage interactions with FDA in an effort to find potential efficiencies as well as inform upcoming legislation, including PDUFA VI.

You may also be interested in...



FDA Flexible With Accelerated Approval Evidence, Analysis Finds

Attorneys Sasinowski and Varond write that in some cases weak clinical evidence on the surrogate endpoint was not a barrier, but strong findings on unmet need and rarity usually are necessary for accelerated approval.

PhRMA, BIO’s PDUFA V Application Tracker Could Inform “Course Corrections”

Members will enter data into secure database, allowing trade groups to gauge trends and problems with the PDUFA V application review program – and giving industry a stronger negotiating position for the next user fee round.

PDUFA V: Communications Liaisons Will Help Find Answers, Not Give Them

OND Director John Jenkins warns that new communications staff will not be equipped to deal with specific technical issues, but should be able to answer general questions.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS077624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel